◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

ZIM Laboratories Limited (ZIMLAB) Financial History

Name: ZIM Laboratories Limited (ZIMLAB) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

ZIM Laboratories Limited (ZIMLAB) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Nagpur, India with about 632 employees. Its market capitalization is roughly ₹7 billion. In the fiscal year ended 2026-03-31, ZIMLAB reported ₹3.6B in revenue and ₹58M in net income.

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally.

Interactive charts & full statements →

ZIMLAB Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹3.6B	₹3.6B	₹3.6B	₹3.9B
Gross Profit	₹1.9B	₹1.9B	₹1.8B	₹1.9B
Operating Income (EBIT)	₹111M	₹266M	₹268M	₹353M
Net Income	₹58M	₹122M	₹172M	₹244M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ZIMLAB Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹942M	₹1.1B	₹1.1B	₹887M	₹718M
Gross Profit	₹547M	₹582M	₹601M	₹491M	₹418M
Operating Income (EBIT)	(₹29M)	₹21M	₹78M	₹8M	(₹6M)
Net Income	(₹40M)	₹37M	₹44M	(₹4M)	(₹19M)

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ZIMLAB Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹1M)	(₹1M)	(₹0M)	(₹1M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ZIMLAB Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹5.4B	₹4.7B	₹4.5B	₹3.4B	—
Total Liabilities	₹2.4B	₹2.2B	₹2.1B	₹1.4B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ZIMLAB viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

WANBURY · Wanbury Limited — ₹8 billion
APTX · Apotex Health Corp. — C$8 billion
BAFNAPH · Bafna Pharmaceuticals Limited — ₹8 billion
AMANTA · Amanta Healthcare Limited — ₹7 billion
VALIANTLAB · Valiant Laboratories Limited — ₹7 billion
KILITCH · Kilitch Drugs (India) Limited — ₹7 billion
0460 · Sihuan Pharmaceutical Holdings Group Ltd. — HK$7 billion
6185 · CanSino Biologics Inc. — HK$7 billion

← ZIM All “Z” companies ZINC →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.